UK's NICE gives Roche drug green light for bladder cancer

LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.